openPR Logo
Press release

Worldwide Neuropsychiatric Disorders and Treatment Market is Estimated to Grow at a CAGR of 6.2% till 2023

02-02-2018 06:38 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Market Research Future

Worldwide Neuropsychiatric Disorders and Treatment Market

Market Research Future published a Half-Cooked Research Report on “Global Neuropsychiatric Disorders and Treatment Market Research Report - Forecast to 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.

Neuropsychiatric disorders are mental disorder occur due to disturbance in the function of cerebral system. Neuropsychiatric disorders are most common to the people having more than 65 year’s age. Increasing prevalence of neuropsychiatric disorders across the globe is the major reason for driving the market. Beside this increasing demand for the better treatment and development in the healthcare sector are the major driving factor for the growth of the market. While lack of clinical trial data for neuropsychiatric drugs and long term treatment of this diseases may restrain the growth of the market.

AstraZeneca (UK), GlaxoSmithKline (UK), Universal Health Services Inc. (US), Biogen (US), Boehringer Ingelheim GmbH (Germany), Eli Lilly (US), Bristol-Meyer Squibb (US), Johnson & Johnson (US), Pfizer (US), Wyeth (US), Otsuka Holdings Co. Ltd (Japan), Astellas Pharma Inc. (Japan) are some of the prominent players at the forefront of competition in the Global neuropsychiatric disorders and treatment Market and are profiled in MRFR Analysis.

Get a sample report at https://www.marketresearchfuture.com/sample_request/1281 .

Geographically, North America accounts for the largest market for the neuropsychiatric disorders and treatment which is slightly less than Europe. Huge population suffering from neuropsychiatric disorders in this region is the major reason for the development of the market. According to WHO the number of patients suffering from neuropsychiatric disorders will be doubled in next couple of decades due to increasing aging population in North America and Europe. Asia Pacific has the third leading market which is expecting a fastest growth in this market due to rapid development in healthcare sector and increasing demand for the better treatment of the neuropsychiatric disorders.

Global Neuropsychiatric Disorders and Treatment Market - Competitive Analysis

Many factors are fuelling the growth of the market. This has attracted many of the manufacturer for development of the market in this sector. Increasing in alliances amongst the leading player has helped to introduction of new and better treatment for the neuropsychiatric disorders.

AstraZeneca is a multinational pharmaceutical and biopharmaceutical company headquartered in UK. Recently AstraZeneca has completed its collaboration with National Institute of Mental Health. This collaboration will help to discover the new and better drug treatment for distressing condition. AstraZeneca has also collaborated with Vanderbilt Center for the Neuroscience Drug Discovery which aims to discover new drug for the treatment of neuropsychiatric disorders.

Universal Health Services is an American Fortune 500 company headquartered in US. It is one of the largest hospital management companies in US. Universal Health Services is a huge company with the revenues of nearly USD 9.7 billion with the profit of more than USD 600 million.

Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies headquartered in Germany. In 2016, Boehringer Ingelheim is collaborated with Saniona. This collaboration aims to develop the new treatment for the patients suffering from schizophrenia.

Browse Complete Report at https://www.marketresearchfuture.com/reports/neuropsychiatric-disorders-treatment-market-1281 .

Global Neuropsychiatric Disorders and Treatment Market- Regional Analysis

On regional basis, global neuropsychiatric disorders and treatment market is segmented into North America, Europe, Asia Pacific and Middle East and Africa. North America commands the largest market for the neuropsychiatric disorders and treatment. In North America neuropsychiatric disorders account the highest rate of disability-adjusted life year (DALYs). DALYs is a measure of overall disease burden which express the number of years lost due to ill health or early death. According to Centers for Disease Control and Prevention, around 5.3 million Americas are suffering from this diseases and this number is expected get double in next couple of decades due to due to the aging of the population. This increasing number of the neuropsychiatric patients in North America has led to the growth of this market in North America.

Europe commands the second largest market for the neuropsychiatric disorders and treatment. Huge population suffering from mental disorders in Iceland, Norway and Switzerland has contributed a lot for the European market. Moreover, increasing demand for need of better treatment and increasing burden of neuropsychiatric disorders are the major factor for the growth of the market.

Neuropsychiatric disorders and treatment market in Asia Pacific is growing at a steady pace due to huge geriatric population in this area, continuous improving healthcare infrastructure and rapid development in healthcare sector has boosted growth of this market. The Middle East and Africa has least market for the neuropsychiatric disorders and treatment.

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us
Market Research Future
Maharashtra, India
+1 646 845 9312
Email: sales@Marketresearchfuture.Com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Worldwide Neuropsychiatric Disorders and Treatment Market is Estimated to Grow at a CAGR of 6.2% till 2023 here

News-ID: 929478 • Views:

More Releases from Market Research Future

Hydrofluoric Acid Market (CAGR) of 4%, Innovation Imperative Future Proofing Your Business with Market Size
Hydrofluoric Acid Market (CAGR) of 4%, Innovation Imperative Future Proofing You …
Hydrofluoric acid (HF) is a crucial chemical compound with a wide range of applications across various industries. Despite its hazardous nature, it plays an essential role in manufacturing processes, especially in the production of fluorine compounds. The global hydrofluoric acid market has been witnessing steady growth, driven by demand from end-user industries such as oil refining, pharmaceuticals, and electronics. The Hydrodesulfurization Catalysts Market is projected to register a CAGR of over
Palm Methyl Ester Derivative Market Size Projected to Grow at 5.92% CAGR, Reaching USD 2.4 billion by 2030
Palm Methyl Ester Derivative Market Size Projected to Grow at 5.92% CAGR, Reachi …
In recent years, the global market for palm methyl ester derivatives has witnessed significant growth, driven by various factors including environmental concerns, technological advancements, and the increasing demand for sustainable alternatives in various industries. Palm methyl ester derivatives, derived from palm oil, have emerged as versatile ingredients with applications spanning across sectors such as cosmetics, pharmaceuticals, lubricants, and more. The Palm Methyl Ester Derivative Market Size was valued at USD 1.5
Asia-Pacific Ceramic Tiles Market to Register Highest CAGR Growth of 7.50% by 2032: Analysis by Segmentation, Competitors Analysis
Asia-Pacific Ceramic Tiles Market to Register Highest CAGR Growth of 7.50% by 20 …
The Asia-Pacific ceramic tiles market has been witnessing robust growth, driven by various factors such as increasing investments in residential and commercial construction, renovation activities, and the growing preference for aesthetically pleasing and durable flooring solutions. Countries like China, India, Japan, and South Korea have been leading the market growth, supported by strong manufacturing capabilities, technological advancements, and evolving consumer preferences. Asia-Pacific Ceramic Tiles Market Size was valued at USD 141.2
APAC Wallpaper Market to Register Highest CAGR Growth of 8% by 2032: Analysis by Segmentation, Competitors Analysis
APAC Wallpaper Market to Register Highest CAGR Growth of 8% by 2032: Analysis by …
The APAC wallpaper market has witnessed significant growth in recent years, driven by factors such as rising disposable incomes, expanding construction activities, and growing awareness regarding interior decor. Countries like China, India, Japan, South Korea, and Australia have emerged as key contributors to the region's wallpaper market. Additionally, the increasing adoption of innovative wallpaper designs and patterns is fueling market growth further. APAC Wallpaper Market Size was valued at USD 0.55

All 5 Releases


More Releases for Neuropsychiatric

New Study Offers Detailed Insights on Paediatric Neuropsychiatric Disorders Trea …
Neuropsychiatry is concerned with study of mental disorders of nervous system that arises from overt function of cerebral system. Paediatric neuropsychiatry is a clinical discipline pertaining to the study of diagnosis and treatment of behavioural and psychiatric disorders in infants, children and adolescents. There are several factors which are hampering the functions of nervous system and cerebral function that lead to paediatric neuropsychiatric diseases. Paediatric neuropsychiatric disorders mainly caused due
Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Researchmoz added Most up-to-date research on "Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017" to its huge collection of research reports. Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017 Summary This report provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), Depression, Schizophrenia, and Tourette syndrome, and features dormant
Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness, with symptoms including disorganized work habits, procrastination and inability to sustain attention on tasks or activities. Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems,
Neuropsychiatric Disorders And Treatment Market: Sturdy Expansion CAGR of 6.2% b …
Market Research Future published a research report on “Neuropsychiatric Disorders And Treatment Market Research Report- Global Forecast To 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023. Global Neuropsychiatric Disorders And Treatment Market Research Report, By Disorders (Degenerative Diseases, Neurotic Disorders, Psychosis And Others), By Treatments (Shock Treatment, Drug Treatment, Others) By End Users (Hospitals, Clinics, Research Centers And Others) - Forecast Till 2023 Market Scenario: Neuropsychiatric is the
Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017 | Now A …
Researchmoz added Most up-to-date research on "Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017" to its huge collection of research reports. This report provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), Depression, Schizophrenia, and Tourette syndrome, and features dormant and discontinued projects. To Get Sample Copy of
Neuropsychiatric Disorder Cluster Drug Development Pipeline Review and Therapeut …
Market Research Hub includes new market research report "Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017" to its huge collection of research reports. This report provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), Depression, Schizophrenia, and Tourette syndrome, and features dormant and discontinued projects. Request Free Sample